XBiotech (XBIT) Capital Expenditures (2014 - 2025)

XBiotech has reported Capital Expenditures for 12 years, with the latest figure at $34000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures fell 59.52% year-over-year to $34000.0 in Q4 2025; TTM through Dec 2025 was $289000.0, a 77.84% decrease from a year earlier, with the FY2025 full-year figure at $289000.0, down 77.84% from the prior year.
• Capital Expenditures was $34000.0 for Q4 2025 at XBiotech, down from $110000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $1.7 million in Q2 2021, with the low at $14000.0 in Q1 2023.
• Average Capital Expenditures over 5 years is $303250.0, with a median of $146500.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures slumped 95.21% in 2022, then surged 1721.43% in 2024.
• Over 5 years, Capital Expenditures stood at $476000.0 in 2021, then tumbled by 72.27% to $132000.0 in 2022, then slipped by 12.88% to $115000.0 in 2023, then slipped by 26.96% to $84000.0 in 2024, then tumbled by 59.52% to $34000.0 in 2025.
• The last three Capital Expenditures figures came in at $34000.0 (Q4 2025), $110000.0 (Q3 2025), and $51000.0 (Q2 2025), per Business Quant data.